Literature DB >> 29691891

Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.

Dirk R J Kuypers1, Thomas Vanhove.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29691891      PMCID： PMC6005618          DOI： 10.1111/bcp.13592

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-02-27       Impact factor: 4.335

2.  Pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?

Authors:  E van Maarseveen; A D van Zuilen
Journal:  Clin Pharmacol Ther       Date:  2012-10-24       Impact factor: 6.875

3.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Transporters.

Authors:  Stephen Ph Alexander; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

4.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

5.  Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

Authors:  Sibylle Neuhoff; Geoffrey T Tucker
Journal:  Br J Clin Pharmacol       Date:  2018-02-21       Impact factor: 4.335

6.  Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.

Authors:  Thomas Vanhove; Mahmoud Hasan; Pieter Annaert; Stefan Oswald; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2017-07-14       Impact factor: 4.335

7.  Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?

Authors:  D Tomalik-Scharte; D Lütjohann; O Doroshyenko; D Frank; A Jetter; U Fuhr
Journal:  Clin Pharmacol Ther       Date:  2009-05-20       Impact factor: 6.875

8.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Authors:  Thomas Vanhove; Hylke de Jonge; Henriëtte de Loor; Pieter Annaert; Ulf Diczfalusy; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

9.  Metabolism of 4 beta -hydroxycholesterol in humans.

Authors:  Karl Bodin; Ulla Andersson; Eva Rystedt; Ewa Ellis; Maria Norlin; Irina Pikuleva; Gösta Eggertsen; Ingemar Björkhem; Ulf Diczfalusy
Journal:  J Biol Chem       Date:  2002-06-20       Impact factor: 5.157

10.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors.

Authors:  Stephen Ph Alexander; John A Cidlowski; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739
View more
  2 in total

1.  Kuypers and Vanhove reply to 'Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?' by Neuhoff and Tucker.

Authors:  Dirk R J Kuypers; Thomas Vanhove
Journal:  Br J Clin Pharmacol       Date:  2018-04-24       Impact factor: 4.335

2.  Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.

Authors:  Kine Eide Kvitne; Kristine Hole; Veronica Krogstad; Birgit Malene Wollmann; Christine Wegler; Line K Johnson; Jens K Hertel; Per Artursson; Cecilia Karlsson; Shalini Andersson; Tommy B Andersson; Rune Sandbu; Jøran Hjelmesæth; Eva Skovlund; Hege Christensen; Rasmus Jansson-Löfmark; Anders Åsberg; Espen Molden; Ida Robertsen
Journal:  Eur J Clin Pharmacol       Date:  2022-06-01       Impact factor: 3.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.